Amylyx Pharmaceuticals, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

Amylyx Pharmaceuticals, Inc. reported Cash And Cash Equivalents At Carrying Value of $226.65 million for the year ending 2025.

  • Amylyx Pharmaceuticals, Inc. showed an increase of +192.9% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from Amylyx Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
  • XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 5 years of available data (2021 to 2025), Amylyx Pharmaceuticals, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 351.6%.
  • Historical annual values: Fiscal year 2025: $226.65 million | Fiscal year 2024: $77.39 million | Fiscal year 2023: $170.20 million | Fiscal year 2022: $62.53 million | Fiscal year 2021: $50.19 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: